Hospital
Denver Health and Hospital Authority
Denver Health and Hospital Authority was paid $77.00M by Medicaid between Jan 2018 and Dec 2024, across 481 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoDENVER HEALTH AND HOSPITAL AUTHORITY
DENVER, CO 80204
DENVER, CO 80204
33aNPI1689624686assigned 05/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$77.00M
24GClaims3,756,991
24DCodes billed481
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#2 of 51
Median peer was paid$1.24M
This provider vs. median62×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official AUDAIN, APRIL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 948,292 | $12.31M | |
| 2019 | 629,072 | $8.78M | |
| 2020 | 462,984 | $6.44M | |
| 2021 | 469,103 | $8.20M | |
| 2022 | 419,769 | $11.35M | |
| 2023 | 479,885 | $15.92M | |
| 2024incomplete | 347,886 | $13.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 104,901 | 89,253 | $10.84M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 85,039 | 73,565 | $9.10M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.9% | 27,869 | 23,522 | $6.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 40,131 | 35,194 | $6.14M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.5% | 405,919 | 193,309 | $4.24M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.1% | 116,555 | 92,780 | $2.41M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.7% | 116,538 | 92,738 | $2.08M |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.1% | 168,620 | 135,364 | $1.58M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.0% | 996 | 909 | $1.53M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 6,507 | 5,674 | $1.42M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 50,147 | 38,602 | $1.31M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 7,962 | 6,611 | $1.09M |
469 more codes
| 83036 | Hemoglobin; glycosylated (A1C) | 1.2% | 126,493 | $962K |
| 80053 | Comprehensive metabolic panel | 1.2% | 89,671 | $946K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.2% | 1,898 | $929K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 11,736 | $716K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 46,617 | $707K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,874 | $697K |
| 46607 | <1% | 1,751 | $611K | |
| 81003 | <1% | 51,921 | $528K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,495 | $511K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 2,748 | $509K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,518 | $508K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,445 | $506K |
| 92015 | Determination of refractive state | <1% | 45,689 | $501K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 81,766 | $494K |
| 85027 | <1% | 185,557 | $492K | |
| 87536 | <1% | 9,150 | $485K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 19,391 | $483K |
| 81025 | <1% | 22,693 | $473K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 13,952 | $436K |
| 95886 | <1% | 3,945 | $412K | |
| 80061 | Lipid panel | <1% | 58,163 | $410K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 64,413 | $396K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 7,023 | $386K |
| 27447 | <1% | 132 | $348K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 599 | $345K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 48,990 | $321K |
| 81001 | <1% | 19,891 | $300K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 23,501 | $293K |
| 92060 | <1% | 7,129 | $290K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 95,570 | $289K |
| 84484 | <1% | 26,105 | $285K | |
| 64615 | <1% | 1,158 | $285K | |
| 87631 | <1% | 7,552 | $281K | |
| 97803 | <1% | 3,598 | $266K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 24,267 | $261K |
| 86480 | <1% | 9,061 | $257K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 11,331 | $256K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,910 | $248K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 26,309 | $240K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 66,554 | $223K |
| 36415 | Collection of venous blood by venipuncture | <1% | 378,446 | $220K |
| 83655 | <1% | 10,141 | $215K | |
| 86780 | <1% | 19,775 | $215K | |
| 52000 | <1% | 679 | $205K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,863 | $204K |
| 87210 | <1% | 19,118 | $200K | |
| 80320 | <1% | 3,030 | $195K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 6,078 | $188K |
| 92134 | <1% | 13,574 | $187K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 553 | $186K |
| 73110 | <1% | 4,891 | $182K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,518 | $176K |
| 92567 | <1% | 9,143 | $172K | |
| 20610 | <1% | 2,175 | $171K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 967 | $170K |
| 73630 | <1% | 5,542 | $169K | |
| 94060 | <1% | 3,842 | $168K | |
| 97010 | <1% | 9,570 | $160K | |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 186 | $157K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,025 | $155K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,951 | $143K |
| 31575 | <1% | 1,361 | $141K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 15,856 | $135K |
| 62323 | <1% | 981 | $134K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 8,150 | $130K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 932 | $129K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 1,522 | $116K |
| 51798 | <1% | 2,785 | $116K | |
| 80076 | <1% | 24,276 | $114K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 828 | $109K |
| 97165 | <1% | 3,115 | $107K | |
| G0378 | Hospital observation service, per hour | <1% | 3,002 | $102K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,576 | $100K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 10,923 | $96K |
| 76942 | <1% | 2,254 | $95K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,205 | $94K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,765 | $93K |
| 86803 | <1% | 16,166 | $88K | |
| 0002A | <1% | 6,090 | $87K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 166 | $86K |
| 73130 | <1% | 2,315 | $86K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,759 | $84K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,339 | $83K |
| 86592 | <1% | 6,066 | $83K | |
| 92558 | <1% | 7,046 | $81K | |
| 93970 | <1% | 823 | $80K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,760 | $78K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,923 | $75K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,181 | $75K |
| 0001A | <1% | 5,436 | $73K | |
| 73610 | <1% | 2,321 | $73K | |
| 20611 | <1% | 335 | $71K | |
| 86361 | <1% | 4,885 | $70K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 95,028 | $68K |
| 97161 | <1% | 3,922 | $66K | |
| 94726 | <1% | 2,367 | $66K | |
| 96415 | <1% | 477 | $65K | |
| 93017 | <1% | 1,438 | $63K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 7,195 | $62K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 990 | $62K |
| 97802 | <1% | 537 | $62K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 16,513 | $61K |
| 96367 | <1% | 762 | $61K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 1,880 | $60K |
| 86703 | <1% | 4,053 | $57K | |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | <1% | 29 | $57K |
| 93922 | <1% | 1,284 | $57K | |
| 29848 | <1% | 44 | $56K | |
| 86140 | <1% | 6,326 | $54K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,102 | $54K |
| 95957 | <1% | 779 | $51K | |
| 92083 | <1% | 1,284 | $51K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,145 | $50K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,124 | $49K |
| 73562 | <1% | 1,477 | $49K | |
| 59025 | Fetal non-stress test | <1% | 445 | $45K |
| 97162 | <1% | 3,501 | $44K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 290 | $43K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 104 | $43K |
| 81002 | <1% | 6,107 | $42K | |
| 92133 | <1% | 2,212 | $40K | |
| 92557 | <1% | 1,932 | $40K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 672 | $39K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 820 | $39K |
| 83986 | <1% | 4,373 | $38K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 2,532 | $37K |
| 88142 | <1% | 3,954 | $36K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 13,015 | $36K |
| 87340 | <1% | 6,046 | $36K | |
| 94729 | <1% | 2,584 | $35K | |
| 87390 | <1% | 4,136 | $34K | |
| 95813 | <1% | 112 | $32K | |
| 52356 | <1% | 12 | $31K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 15 | $30K |
| 80348 | <1% | 660 | $30K | |
| 19083 | <1% | 70 | $29K | |
| 92136 | <1% | 1,357 | $28K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 4,762 | $28K |
| 86682 | <1% | 2,016 | $27K | |
| 84439 | <1% | 3,323 | $26K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,949 | $26K |
| 95812 | <1% | 119 | $26K | |
| 46615 | <1% | 34 | $25K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 362 | $25K |
| 93296 | <1% | 1,633 | $25K | |
| 64415 | <1% | 237 | $25K | |
| 83020 | <1% | 1,402 | $24K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 347 | $24K |
| 87070 | <1% | 1,388 | $23K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 277 | $22K |
| 67228 | <1% | 27 | $22K | |
| 73030 | <1% | 416 | $21K | |
| 43235 | <1% | 84 | $21K | |
| 87081 | <1% | 1,325 | $21K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,070 | $21K |
| 80361 | <1% | 709 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,627 | $20K |
| 86359 | <1% | 1,368 | $19K | |
| 76642 | <1% | 252 | $18K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,206 | $18K |
| 86360 | <1% | 1,368 | $17K | |
| 93926 | <1% | 248 | $17K | |
| 82565 | <1% | 1,905 | $17K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 18 | $17K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,725 | $17K |
| 92523 | <1% | 275 | $16K | |
| 84460 | <1% | 5,636 | $16K | |
| 83498 | <1% | 1,421 | $16K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 54 | $15K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,613 | $15K |
| 86704 | <1% | 1,945 | $15K | |
| 23430 | <1% | 12 | $14K | |
| 49083 | <1% | 23 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 50,447 | $14K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 951 | $14K |
| 88112 | <1% | 2,264 | $14K | |
| 83605 | <1% | 703 | $14K | |
| 93299 | <1% | 1,227 | $13K | |
| 92025 | <1% | 735 | $13K | |
| 82728 | <1% | 1,795 | $13K | |
| 90688 | <1% | 7,731 | $12K | |
| 97760 | <1% | 1,987 | $11K | |
| 84703 | <1% | 6,358 | $11K | |
| 73564 | <1% | 265 | $11K | |
| 86762 | <1% | 1,002 | $11K | |
| 95885 | <1% | 94 | $11K | |
| 76830 | Ultrasound, transvaginal | <1% | 102 | $11K |
| 85652 | <1% | 5,279 | $11K | |
| 86706 | <1% | 1,834 | $11K | |
| 80365 | <1% | 709 | $10K | |
| C1776 | Joint device (implantable) | <1% | 264 | $10K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 752 | $10K |
| 84030 | <1% | 1,401 | $10K | |
| 90686 | <1% | 553 | $10K | |
| 92555 | <1% | 1,129 | $10K | |
| 73590 | <1% | 254 | $9K | |
| 84437 | <1% | 1,401 | $9K | |
| 94664 | <1% | 275 | $9K | |
| 73140 | <1% | 256 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 28,875 | $9K |
| 95816 | <1% | 90 | $9K | |
| 96402 | <1% | 247 | $8K | |
| 92586 | <1% | 38 | $8K | |
| 51741 | <1% | 201 | $8K | |
| 95819 | <1% | 70 | $8K | |
| 97163 | <1% | 1,159 | $8K | |
| 93298 | <1% | 256 | $8K | |
| 82465 | <1% | 1,662 | $8K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 197 | $7K |
| 94010 | <1% | 288 | $7K | |
| 82570 | <1% | 1,547 | $7K | |
| 97129 | <1% | 270 | $7K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 86 | $7K |
| 97116 | <1% | 1,209 | $7K | |
| 82607 | <1% | 1,001 | $7K | |
| 11750 | <1% | 40 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 109 | $7K |
| 82043 | <1% | 324 | $7K | |
| 86708 | <1% | 1,362 | $7K | |
| 80305 | <1% | 544 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 106 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,422 | $6K |
| 77065 | Tomosynthesis, mammo | <1% | 333 | $6K |
| 86850 | <1% | 651 | $6K | |
| 86300 | <1% | 389 | $6K | |
| 92579 | <1% | 324 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 21,131 | $6K |
| 85610 | <1% | 3,979 | $6K | |
| 97033 | <1% | 841 | $6K | |
| 97014 | <1% | 1,069 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,292 | $6K |
| 11721 | <1% | 494 | $6K | |
| 94618 | <1% | 82 | $5K | |
| 11045 | <1% | 13 | $5K | |
| 72120 | <1% | 160 | $5K | |
| 86160 | <1% | 984 | $5K | |
| 74183 | <1% | 28 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 93 | $5K |
| 11057 | <1% | 134 | $5K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,044 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,184 | $5K |
| 97542 | <1% | 704 | $4K | |
| 72040 | <1% | 107 | $4K | |
| 87507 | <1% | 43 | $4K | |
| 83540 | <1% | 1,457 | $4K | |
| 81401 | <1% | 206 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 24,646 | $4K |
| 31231 | <1% | 27 | $4K | |
| 20550 | <1% | 32 | $4K | |
| 85014 | <1% | 631 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,186 | $4K |
| 83615 | <1% | 2,828 | $4K | |
| 10005 | <1% | 14 | $3K | |
| 83550 | <1% | 906 | $3K | |
| 95909 | <1% | 224 | $3K | |
| 83690 | <1% | 11,102 | $3K | |
| 84450 | <1% | 1,298 | $3K | |
| 82247 | <1% | 138 | $3K | |
| 76813 | <1% | 86 | $3K | |
| 83880 | <1% | 229 | $3K | |
| 93798 | <1% | 57 | $3K | |
| 80329 | <1% | 89 | $3K | |
| 93308 | <1% | 27 | $3K | |
| H0031 | Mental health assessment, by non-physician | <1% | 210 | $3K |
| 70491 | <1% | 12 | $3K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 746 | $3K |
| 87116 | <1% | 248 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 5,943 | $3K |
| 92504 | <1% | 43 | $3K | |
| 93225 | <1% | 155 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,832 | $2K |
| 87015 | <1% | 246 | $2K | |
| 86900 | <1% | 678 | $2K | |
| 80069 | <1% | 413 | $2K | |
| 88342 | <1% | 2,238 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,760 | $2K |
| 93924 | <1% | 26 | $2K | |
| 73221 | <1% | 14 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,845 | $2K |
| 90837 | Psychotherapy session, about an hour | <1% | 72 | $2K |
| 86787 | <1% | 563 | $2K | |
| 87205 | <1% | 87 | $2K | |
| 73560 | <1% | 265 | $2K | |
| 78451 | <1% | 25 | $2K | |
| 93971 | <1% | 13 | $2K | |
| 83883 | <1% | 154 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,586 | $2K |
| 73070 | <1% | 27 | $2K | |
| 82378 | <1% | 343 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 385 | $1K |
| 97026 | <1% | 110 | $1K | |
| 73502 | <1% | 47 | $1K | |
| 88173 | <1% | 82 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,798 | $1K |
| 81508 | <1% | 57 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 32,981 | $1K |
| 87088 | <1% | 189 | $1K | |
| 82784 | <1% | 272 | $1K | |
| 95910 | <1% | 79 | $1K | |
| 69210 | <1% | 49 | $1K | |
| 82977 | <1% | 422 | $1K | |
| 76770 | <1% | 12 | $1K | |
| 82105 | <1% | 64 | $1K | |
| 95912 | <1% | 37 | $1K | |
| 84156 | <1% | 690 | $1K | |
| 83970 | <1% | 90 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 11,759 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 814 | $1K |
| 87556 | <1% | 48 | $1K | |
| 11056 | <1% | 20 | $1K | |
| 11055 | <1% | 12 | $1K | |
| 86735 | <1% | 360 | $1K | |
| 86901 | <1% | 678 | $1K | |
| 86765 | <1% | 360 | $983.14 | |
| 95913 | <1% | 12 | $981.06 | |
| 93226 | <1% | 153 | $946.48 | |
| 84153 | <1% | 138 | $911.95 | |
| 88304 | <1% | 381 | $892.96 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 894 | $889.86 |
| 82950 | <1% | 248 | $889.34 | |
| 29075 | <1% | 21 | $869.98 | |
| 82274 | <1% | 86 | $862.69 | |
| 76519 | <1% | 14 | $804.42 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 7,026 | $788.31 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 507 | $767.58 |
| 97799 | <1% | 568 | $765.12 | |
| 87206 | <1% | 226 | $761.44 | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 19 | $746.40 |
| 84134 | <1% | 280 | $729.63 | |
| 72190 | <1% | 14 | $724.42 | |
| 99406 | <1% | 53 | $723.24 | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 58 | $702.99 |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 1,848 | $702.99 |
| 84403 | <1% | 203 | $696.20 | |
| 82962 | <1% | 10,021 | $694.10 | |
| 71250 | <1% | 17 | $678.92 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 116 | $668.55 |
| 90656 | <1% | 36 | $648.01 | |
| 77080 | <1% | 19 | $647.91 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,868 | $639.83 |
| 96368 | <1% | 28 | $618.13 | |
| 0012A | <1% | 86 | $616.52 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 582 | $602.68 |
| 85018 | <1% | 99 | $600.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 48 | $551.29 |
| 0011A | <1% | 116 | $529.92 | |
| 83993 | <1% | 58 | $519.97 | |
| 97164 | <1% | 89 | $513.76 | |
| 99152 | <1% | 6,228 | $512.78 | |
| 84480 | <1% | 142 | $511.57 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $477.33 |
| D0190 | <1% | 1,373 | $460.44 | |
| 97166 | <1% | 19 | $460.11 | |
| 74210 | <1% | 12 | $443.32 | |
| 80050 | General health panel | <1% | 39 | $441.96 |
| 86677 | <1% | 39 | $438.03 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 7,270 | $413.82 |
| 82365 | <1% | 17 | $409.06 | |
| 88311 | <1% | 248 | $367.64 | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $366.88 |
| 87517 | <1% | 13 | $329.50 | |
| 84425 | <1% | 92 | $320.71 | |
| 87902 | <1% | 15 | $319.47 | |
| 84478 | <1% | 66 | $318.03 | |
| 93325 | <1% | 32 | $316.12 | |
| 86593 | <1% | 64 | $311.66 | |
| 82550 | <1% | 32 | $282.14 | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 283 | $275.06 |
| 85049 | <1% | 99 | $266.41 | |
| 92650 | <1% | 14 | $261.00 | |
| 84702 | <1% | 44 | $260.22 | |
| 92526 | <1% | 161 | $247.77 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 1,177 | $222.67 |
| 93289 | <1% | 12 | $212.82 | |
| 82525 | <1% | 20 | $210.33 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 56 | $202.93 |
| 82310 | <1% | 57 | $192.79 | |
| 95908 | <1% | 93 | $182.53 | |
| 90480 | <1% | 13 | $173.41 | |
| 86225 | <1% | 89 | $152.69 | |
| 85007 | <1% | 46 | $145.10 | |
| 81329 | <1% | 13 | $141.52 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 15 | $134.22 |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 43 | $132.16 |
| 84402 | <1% | 18 | $117.47 | |
| 84146 | <1% | 13 | $116.58 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 204 | $107.02 |
| 84630 | <1% | 20 | $105.26 | |
| 90674 | <1% | 222 | $103.98 | |
| 36591 | <1% | 314 | $101.58 | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 79 | $96.96 |
| 97130 | <1% | 218 | $89.05 | |
| 92553 | <1% | 23 | $84.54 | |
| 20560 | <1% | 615 | $82.76 | |
| 0072A | <1% | 12 | $82.36 | |
| 87338 | <1% | 13 | $76.40 | |
| 82040 | <1% | 40 | $66.97 | |
| 82746 | <1% | 21 | $61.40 | |
| 93288 | <1% | 25 | $55.75 | |
| 87077 | <1% | 15 | $48.91 | |
| 96401 | <1% | 17 | $44.62 | |
| 20561 | <1% | 441 | $41.38 | |
| 85730 | <1% | 39 | $39.53 | |
| 36416 | <1% | 1,792 | $31.85 | |
| 84520 | <1% | 29 | $19.08 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 451 | $15.60 |
| 85048 | <1% | 13 | $14.62 | |
| 99499 | <1% | 40 | $7.92 | |
| 83735 | <1% | 487 | $7.41 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,882 | $4.41 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,032 | $0.13 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 314 | $0.00 |
| G0467 | Community health center visit, returning patient | 0% | 7,520 | $0.00 |
| 90474 | 0% | 2,810 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 945 | $0.00 |
| C1769 | Guide wire | 0% | 184 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 829 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 103 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 26 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 674 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 237 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 230 | $0.00 |
| 96376 | 0% | 165 | $0.00 | |
| 92551 | 0% | 384 | $0.00 | |
| 97035 | 0% | 78 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 79 | $0.00 |
| 92556 | 0% | 12 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 141 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 15 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 21 | $0.00 |
| 76377 | 0% | 24 | $0.00 | |
| H0025 | Behavioral health prevention education service (delivery of services with target population to affect knowledge, attitude and/or behavior) | 0% | 29 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 13 | $0.00 |
| 99239 | Hospital discharge day management, more than 30 minutes | 0% | 33 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 50 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 14 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 47 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 235 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 358 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 570 | $0.00 |
| 76376 | 0% | 86 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 1,959 | $0.00 |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | 0% | 94 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 85 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 573 | $0.00 |
| 90648 | 0% | 221 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 190 | $0.00 |
| 0003A | 0% | 32 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 104 | $0.00 |
| 0013A | 0% | 92 | $0.00 | |
| 99204 | Doctor's office visit, new patient (more involved) | 0% | 695 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 61 | $0.00 |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 231 | $0.00 |
| 84100 | 0% | 36 | $0.00 | |
| V2630 | Anterior chamber intraocular lens | 0% | 76 | $0.00 |
| 96417 | 0% | 245 | $0.00 | |
| 99173 | 0% | 725 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 109 | $0.00 |
| 82075 | 0% | 54 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 12 | $0.00 |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 0% | 13 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 82 | $0.00 |
| 90633 | 0% | 47 | $0.00 | |
| 93321 | 0% | 27 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 12 | $0.00 |
| 99442 | 0% | 13 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 12 | $0.00 |
| 92552 | 0% | 12 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAUDAIN, APRIL (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.